English

Ernexa Therapeutics Inc.

EDGAR

BTX Current report (8-K) · filed 2026-10-15

Annual consolidated revenue for 2024: about USD 582K, using the latest reported figures. The previous period, 2023, was about USD 68K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1 thousand USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 582000 USD Source
Revenue: 581000 USD Source

Operating margin

-269,700%

2024 Q4 · %

Exact inputs and evidence

Operating Income: -15674000 USD Source
Operating Income: -12977000 USD Source
Revenue: 582000 USD Source
Revenue: 581000 USD Source

Operating cash flow

-3.55 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -15836000 USD Source
Operating Cash Flow: -12291000 USD Source

Free cash flow

-3.55 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -15836000 USD Source
Operating Cash Flow: -12291000 USD Source
Capital Expenditure: 369000 USD Source
Capital Expenditure: 369000 USD Source

Cash and cash equivalents: 4.32 million USD 2025-06-30 Source
Exact value

4315000 USD
Long-term debt including current maturities: 725 thousand USD 2020-09-30 Source
Exact value

725000 USD
Shares outstanding: 1.17 million shares 2026-06-30 Source
Exact value

1170000 shares

Reported share-count change

-84.36% · -6.31 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

7483000 shares · 2025-06-30· Source
1170000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

582 thousand USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Revenue: 47000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 47000 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 487000 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 582000 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 581000 USD · 2024-01-01 – 2024-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-15.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2024-12-31
Operating income: 9 of 11 periods available· newest 2024-12-31
Net income: 9 of 11 periods available· newest 2024-12-31
Operating cash flow: 9 of 11 periods available· newest 2024-12-31
Capital expenditure: 8 of 11 periods available· newest 2024-12-31
Total assets: 9 of 11 periods available· newest 2024-12-31
Total liabilities: 9 of 11 periods available· newest 2024-12-31
Current assets: 9 of 11 periods available· newest 2024-12-31
Current liabilities: 9 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2018-12-31
Shares outstanding: 9 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+755.9%

Prior period

USD 68,000

2023-01-01 – 2023-12-31
Current period

USD 582,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

582000 − 68000 = 514000 USD

68000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
582000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Year-over-year change in Revenue: 514000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 582000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1758175 Filing: 000149315226010102 Input fundies:Revenue: 68000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#2473003 Filing: 000149315225010051
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 22.87 million

Prior period

−USD 21.67 million

2023-01-01 – 2023-12-31
Current period

−USD 44.54 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-44539000 − -21668000 = -22871000 USD

-21668000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-44539000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Year-over-year change in Net income: -22871000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -44539000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1814215 Filing: 000149315226010102 Input fundies:NetIncome: -21668000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#2497252 Filing: 000149315225010051
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 4.57 million

Prior period

−USD 20.41 million

2023-01-01 – 2023-12-31
Current period

−USD 15.84 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-15836000 − -20408000 = 4572000 USD

-20408000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-15836000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Year-over-year change in Operating cash flow: 4572000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -15836000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1578404 Filing: 000149315226010102 Input fundies:OperatingCashFlow: -20408000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#1508058 Filing: 000149315225010051
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+1,842.1%

Prior period

USD 19,000

2023-01-01 – 2023-12-31
Current period

USD 369,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

369000 − 19000 = 350000 USD

19000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
369000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Year-over-year change in Capital expenditure: 350000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 369000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1581064 Filing: 000149315226010102 Input fundies:CapitalExpenditure: 19000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#1510703 Filing: 000149315225010051
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 582,000 100% of revenue
Cost of revenue USD 96,000 16% of revenue
Operating expenses USD 16.16 million 2,777% of revenue
Operating income −USD 15.67 million −2,693% of revenue
Tax, interest and other Derived USD 28.87 million 4,960% of revenue
Net income −USD 44.54 million −7,653% of revenue

Cash

Operating cash flow −USD 15.84 million −2,721% of revenue
Capital expenditure USD 369,000 63% of revenue
Free cash flow Derived −USD 16.21 million −2,784% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 118% of revenue.
2015 Operating loss: operating costs were 128% of revenue.
2016 Operating loss: operating costs were 110% of revenue.
2017 Operating loss: operating costs were 107% of revenue.
2018 Net loss: net income was −1.1% of revenue.
2019 Operating loss: operating costs were 109% of revenue.
2020 Operating loss: operating costs were 209% of revenue.
2023 Operating loss: operating costs were 31,181% of revenue.
2024 Operating loss: operating costs were 2,793% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	26046000	30788000 Derived	-4742000	288000 Derived	-5030000	-7220000 Derived	Source 2014-01-01 – 2014-12-31: 26046000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -4742000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -5030000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -6385000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 835000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	24519000	31414000 Derived	-6895000	331000 Derived	-7226000	-5171000 Derived	Source 2015-01-01 – 2015-12-31: 24519000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -6895000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -7226000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -4180000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 991000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	22312000	24590000 Derived	-2278000	645000 Derived	-2923000	-404000 Derived	Source 2016-01-01 – 2016-12-31: 22312000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -2278000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -2923000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 23000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 427000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	21274000	22676000 Derived	-1402000	-325000 Derived	-1077000	-179000 Derived	Source 2017-01-01 – 2017-12-31: 21274000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -1402000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -1077000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 549000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 728000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	23335000	23132000 Derived	203000	462000 Derived	-259000	717000 Derived	Source 2018-01-01 – 2018-12-31: 23335000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 203000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -259000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 1365000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 648000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	19806000	21568000 Derived	-1762000	285000 Derived	-2047000	2616000 Derived	Source 2019-01-01 – 2019-12-31: 19806000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -1762000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -2047000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 2744000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 128000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	5800000	12109000 Derived	-6309000	-1894000 Derived	-4415000	Unavailable	Source 2020-01-01 – 2020-12-31: 5800000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -6309000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -4415000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -3894000 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	68000	21203000 Derived	-21135000	533000 Derived	-21668000	-20427000 Derived	Source 2023-01-01 – 2023-12-31: 68000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -21135000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -21668000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -20408000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 19000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	582000	16256000 Derived	-15674000	28865000 Derived	-44539000	-16205000 Derived	Source 2024-01-01 – 2024-12-31: 582000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -15674000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -44539000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -15836000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 369000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 582K 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	26046000	Revenue: 26046000 Open source
20152015-12-31	Revenue	24519000	Revenue: 24519000 Open source
20162016-12-31	Revenue	22312000	Revenue: 22312000 Open source
20172017-12-31	Revenue	21274000	Revenue: 21274000 Open source
20182018-12-31	Revenue	23335000	Revenue: 23335000 Open source
20192019-12-31	Revenue	19806000	Revenue: 19806000 Open source
20202020-12-31	Revenue	5800000	Revenue: 5800000 Open source
20232023-12-31	Revenue	68000	Revenue: 68000 Open source
20242024-12-31	Revenue	582000	Revenue: 582000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

755.9% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 26046000 Open source
20152015-12-31	Year over year	-5.9%	Revenue: 24519000 Open source Revenue: 26046000 Open source
20162016-12-31	Year over year	-9%	Revenue: 22312000 Open source Revenue: 24519000 Open source
20172017-12-31	Year over year	-4.7%	Revenue: 21274000 Open source Revenue: 22312000 Open source
20182018-12-31	Year over year	9.7%	Revenue: 23335000 Open source Revenue: 21274000 Open source
20192019-12-31	Year over year	-15.1%	Revenue: 19806000 Open source Revenue: 23335000 Open source
20202020-12-31	Year over year	-70.7%	Revenue: 5800000 Open source Revenue: 19806000 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 68000 Open source
20242024-12-31	Year over year	755.9%	Revenue: 582000 Open source Revenue: 68000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -2,693.1% 2024

Net margin -7,652.7% 2024

Free cash flow margin -2,784.4% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-18.2%	Operating Income: -4742000 Open source Revenue: 26046000 Open source
20152015-12-31	Operating margin	-28.1%	Operating Income: -6895000 Open source Revenue: 24519000 Open source
20162016-12-31	Operating margin	-10.2%	Operating Income: -2278000 Open source Revenue: 22312000 Open source
20172017-12-31	Operating margin	-6.6%	Operating Income: -1402000 Open source Revenue: 21274000 Open source
20182018-12-31	Operating margin	0.9%	Operating Income: 203000 Open source Revenue: 23335000 Open source
20192019-12-31	Operating margin	-8.9%	Operating Income: -1762000 Open source Revenue: 19806000 Open source
20202020-12-31	Operating margin	-108.8%	Operating Income: -6309000 Open source Revenue: 5800000 Open source
20232023-12-31	Operating margin	-31,080.9%	Operating Income: -21135000 Open source Revenue: 68000 Open source
20242024-12-31	Operating margin	-2,693.1%	Operating Income: -15674000 Open source Revenue: 582000 Open source
20142014-12-31	Net margin	-19.3%	Net Income: -5030000 Open source Revenue: 26046000 Open source
20152015-12-31	Net margin	-29.5%	Net Income: -7226000 Open source Revenue: 24519000 Open source
20162016-12-31	Net margin	-13.1%	Net Income: -2923000 Open source Revenue: 22312000 Open source
20172017-12-31	Net margin	-5.1%	Net Income: -1077000 Open source Revenue: 21274000 Open source
20182018-12-31	Net margin	-1.1%	Net Income: -259000 Open source Revenue: 23335000 Open source
20192019-12-31	Net margin	-10.3%	Net Income: -2047000 Open source Revenue: 19806000 Open source
20202020-12-31	Net margin	-76.1%	Net Income: -4415000 Open source Revenue: 5800000 Open source
20232023-12-31	Net margin	-31,864.7%	Net Income: -21668000 Open source Revenue: 68000 Open source
20242024-12-31	Net margin	-7,652.7%	Net Income: -44539000 Open source Revenue: 582000 Open source
20142014-12-31	Free cash flow margin	-27.7%	Revenue: 26046000 Open source Operating Cash Flow: -6385000 Open source Capital Expenditure: 835000 Open source
20152015-12-31	Free cash flow margin	-21.1%	Revenue: 24519000 Open source Operating Cash Flow: -4180000 Open source Capital Expenditure: 991000 Open source
20162016-12-31	Free cash flow margin	-1.8%	Revenue: 22312000 Open source Operating Cash Flow: 23000 Open source Capital Expenditure: 427000 Open source
20172017-12-31	Free cash flow margin	-0.8%	Revenue: 21274000 Open source Operating Cash Flow: 549000 Open source Capital Expenditure: 728000 Open source
20182018-12-31	Free cash flow margin	3.1%	Revenue: 23335000 Open source Operating Cash Flow: 1365000 Open source Capital Expenditure: 648000 Open source
20192019-12-31	Free cash flow margin	13.2%	Revenue: 19806000 Open source Operating Cash Flow: 2744000 Open source Capital Expenditure: 128000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 5800000 Open source Operating Cash Flow: -3894000 Open source
20232023-12-31	Free cash flow margin	-30,039.7%	Revenue: 68000 Open source Operating Cash Flow: -20408000 Open source Capital Expenditure: 19000 Open source
20242024-12-31	Free cash flow margin	-2,784.4%	Revenue: 582000 Open source Operating Cash Flow: -15836000 Open source Capital Expenditure: 369000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -15.8M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	-6385000	Operating Cash Flow: -6385000 Open source
20152015-12-31	Operating cash flow	-4180000	Operating Cash Flow: -4180000 Open source
20162016-12-31	Operating cash flow	23000	Operating Cash Flow: 23000 Open source
20172017-12-31	Operating cash flow	549000	Operating Cash Flow: 549000 Open source
20182018-12-31	Operating cash flow	1365000	Operating Cash Flow: 1365000 Open source
20192019-12-31	Operating cash flow	2744000	Operating Cash Flow: 2744000 Open source
20202020-12-31	Operating cash flow	-3894000	Operating Cash Flow: -3894000 Open source
20232023-12-31	Operating cash flow	-20408000	Operating Cash Flow: -20408000 Open source
20242024-12-31	Operating cash flow	-15836000	Operating Cash Flow: -15836000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -16.2M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-7220000	Operating Cash Flow: -6385000 Open source Capital Expenditure: 835000 Open source
20152015-12-31	Free cash flow	-5171000	Operating Cash Flow: -4180000 Open source Capital Expenditure: 991000 Open source
20162016-12-31	Free cash flow	-404000	Operating Cash Flow: 23000 Open source Capital Expenditure: 427000 Open source
20172017-12-31	Free cash flow	-179000	Operating Cash Flow: 549000 Open source Capital Expenditure: 728000 Open source
20182018-12-31	Free cash flow	717000	Operating Cash Flow: 1365000 Open source Capital Expenditure: 648000 Open source
20192019-12-31	Free cash flow	2616000	Operating Cash Flow: 2744000 Open source Capital Expenditure: 128000 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -3894000 Open source
20232023-12-31	Free cash flow	-20427000	Operating Cash Flow: -20408000 Open source Capital Expenditure: 19000 Open source
20242024-12-31	Free cash flow	-16205000	Operating Cash Flow: -15836000 Open source Capital Expenditure: 369000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

67.7% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	50.9%	Total Liabilities: 11344000 Open source Total Assets: 22268000 Open source
20152015-12-31	Liabilities / assets	76.5%	Total Liabilities: 12560000 Open source Total Assets: 16408000 Open source
20162016-12-31	Liabilities / assets	75.6%	Total Liabilities: 12627000 Open source Total Assets: 16695000 Open source
20172017-12-31	Liabilities / assets	66.6%	Total Liabilities: 11034000 Open source Total Assets: 16570000 Open source
20182018-12-31	Liabilities / assets	53.5%	Total Liabilities: 7947000 Open source Total Assets: 14864000 Open source
20192019-12-31	Liabilities / assets	64%	Total Liabilities: 9034000 Open source Total Assets: 14125000 Open source
20202020-12-31	Liabilities / assets	77.3%	Total Liabilities: 2894000 Open source Total Assets: 3745000 Open source
20232023-12-31	Liabilities / assets	95.5%	Total Liabilities: 46899000 Open source Total Assets: 49132000 Open source
20242024-12-31	Liabilities / assets	67.7%	Total Liabilities: 3568000 Open source Total Assets: 5269000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.8× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	2.1×	Current Assets: 14872000 Open source Current Liabilities: 7093000 Open source
20152015-12-31	Current assets / current liabilities	1.78×	Current Assets: 9110000 Open source Current Liabilities: 5122000 Open source
20162016-12-31	Current assets / current liabilities	1.6×	Current Assets: 10662000 Open source Current Liabilities: 6643000 Open source
20172017-12-31	Current assets / current liabilities	0.9×	Current Assets: 9638000 Open source Current Liabilities: 10747000 Open source
20182018-12-31	Current assets / current liabilities	1.69×	Current Assets: 6785000 Open source Current Liabilities: 4024000 Open source
20192019-12-31	Current assets / current liabilities	1×	Current Assets: 6070000 Open source Current Liabilities: 6095000 Open source
20202020-12-31	Current assets / current liabilities	0.73×	Current Assets: 1724000 Open source Current Liabilities: 2360000 Open source
20232023-12-31	Current assets / current liabilities	1.46×	Current Assets: 9599000 Open source Current Liabilities: 6573000 Open source
20242024-12-31	Current assets / current liabilities	0.8×	Current Assets: 2352000 Open source Current Liabilities: 2938000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 5.03 million Exact value Exact value: -5030000 USD 2014-01-01 – 2014-12-31: -5030000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2014-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -5030000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5030000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315216008049/ntn-20151231.xml#127218 Filing: 000149315216008049 The citation records this snapshot. The page link may show a newer release later.	−USD 6.39 million Exact value Exact value: -6385000 USD 2014-01-01 – 2014-12-31: -6385000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2014-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: -6385000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6385000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315216008049/ntn-20151231.xml#146452 Filing: 000149315216008049 The citation records this snapshot. The page link may show a newer release later.	USD 835,000 Exact value Exact value: 835000 USD 2014-01-01 – 2014-12-31: 835000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2014-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 835000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 835000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315216008049/ntn-20151231.xml#148188 Filing: 000149315216008049 The citation records this snapshot. The page link may show a newer release later.	−USD 7.22 million Calculation and evidence -6385000 − 835000 USD Exact free cash flow: -7220000 USD 2014-01-01 – 2014-12-31: -6385000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 835000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2014-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: -7220000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6385000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315216008049/ntn-20151231.xml#146452 Filing: 000149315216008049 Input fundies:CapitalExpenditure: 835000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315216008049/ntn-20151231.xml#148188 Filing: 000149315216008049 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 7.23 million Exact value Exact value: -7226000 USD 2015-01-01 – 2015-12-31: -7226000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2015-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -7226000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7226000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315217002280/ntn-20161231.xml#684384 Filing: 000149315217002280 The citation records this snapshot. The page link may show a newer release later.	−USD 4.18 million Exact value Exact value: -4180000 USD 2015-01-01 – 2015-12-31: -4180000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2015-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: -4180000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4180000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315217002280/ntn-20161231.xml#703839 Filing: 000149315217002280 The citation records this snapshot. The page link may show a newer release later.	USD 991,000 Exact value Exact value: 991000 USD 2015-01-01 – 2015-12-31: 991000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2015-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 991000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 991000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315217002280/ntn-20161231.xml#703472 Filing: 000149315217002280 The citation records this snapshot. The page link may show a newer release later.	−USD 5.17 million Calculation and evidence -4180000 − 991000 USD Exact free cash flow: -5171000 USD 2015-01-01 – 2015-12-31: -4180000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 991000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2015-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: -5171000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4180000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315217002280/ntn-20161231.xml#703839 Filing: 000149315217002280 Input fundies:CapitalExpenditure: 991000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315217002280/ntn-20161231.xml#703472 Filing: 000149315217002280 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 2.92 million Exact value Exact value: -2923000 USD 2016-01-01 – 2016-12-31: -2923000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2016-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -2923000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2923000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315218003164/ntn-20171231.xml#115965 Filing: 000149315218003164 The citation records this snapshot. The page link may show a newer release later.	USD 23,000 Exact value Exact value: 23000 USD 2016-01-01 – 2016-12-31: 23000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2016-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: 23000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 23000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315218003164/ntn-20171231.xml#214899 Filing: 000149315218003164 The citation records this snapshot. The page link may show a newer release later.	USD 427,000 Exact value Exact value: 427000 USD 2016-01-01 – 2016-12-31: 427000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2016-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 427000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 427000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315218003164/ntn-20171231.xml#221157 Filing: 000149315218003164 The citation records this snapshot. The page link may show a newer release later.	−USD 404,000 Calculation and evidence 23000 − 427000 USD Exact free cash flow: -404000 USD 2016-01-01 – 2016-12-31: 23000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 427000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2016-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: -404000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 23000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315218003164/ntn-20171231.xml#214899 Filing: 000149315218003164 Input fundies:CapitalExpenditure: 427000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315218003164/ntn-20171231.xml#221157 Filing: 000149315218003164 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 1.08 million Exact value Exact value: -1077000 USD 2017-01-01 – 2017-12-31: -1077000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2017-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -1077000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1077000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315219003770/ntn-20181231.xml#91349 Filing: 000149315219003770 The citation records this snapshot. The page link may show a newer release later.	USD 549,000 Exact value Exact value: 549000 USD 2017-01-01 – 2017-12-31: 549000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2017-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: 549000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 549000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315219003770/ntn-20181231.xml#107755 Filing: 000149315219003770 The citation records this snapshot. The page link may show a newer release later.	USD 728,000 Exact value Exact value: 728000 USD 2017-01-01 – 2017-12-31: 728000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2017-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 728000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 728000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315219003770/ntn-20181231.xml#112683 Filing: 000149315219003770 The citation records this snapshot. The page link may show a newer release later.	−USD 179,000 Calculation and evidence 549000 − 728000 USD Exact free cash flow: -179000 USD 2017-01-01 – 2017-12-31: 549000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 728000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2017-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: -179000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 549000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315219003770/ntn-20181231.xml#107755 Filing: 000149315219003770 Input fundies:CapitalExpenditure: 728000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315219003770/ntn-20181231.xml#112683 Filing: 000149315219003770 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 259,000 Exact value Exact value: -259000 USD 2018-01-01 – 2018-12-31: -259000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2018-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -259000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -259000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#1048028 Filing: 000149315220018754 The citation records this snapshot. The page link may show a newer release later.	USD 1.37 million Exact value Exact value: 1365000 USD 2018-01-01 – 2018-12-31: 1365000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2018-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: 1365000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1365000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#519508 Filing: 000149315220018754 The citation records this snapshot. The page link may show a newer release later.	USD 648,000 Exact value Exact value: 648000 USD 2018-01-01 – 2018-12-31: 648000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2018-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 648000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 648000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#414884 Filing: 000149315220018754 The citation records this snapshot. The page link may show a newer release later.	USD 717,000 Calculation and evidence 1365000 − 648000 USD Exact free cash flow: 717000 USD 2018-01-01 – 2018-12-31: 1365000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 648000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2018-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: 717000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1365000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#519508 Filing: 000149315220018754 Input fundies:CapitalExpenditure: 648000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#414884 Filing: 000149315220018754 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 2.05 million Exact value Exact value: -2047000 USD 2019-01-01 – 2019-12-31: -2047000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2019-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -2047000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2047000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315221005827/ntn-20201231.xml#111730 Filing: 000149315221005827 The citation records this snapshot. The page link may show a newer release later.	USD 2.74 million Exact value Exact value: 2744000 USD 2019-01-01 – 2019-12-31: 2744000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2019-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: 2744000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2744000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315221005827/ntn-20201231.xml#121399 Filing: 000149315221005827 The citation records this snapshot. The page link may show a newer release later.	USD 128,000 Exact value Exact value: 128000 USD 2019-01-01 – 2019-12-31: 128000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2019-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 128000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 128000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#414700 Filing: 000149315220018754 The citation records this snapshot. The page link may show a newer release later.	USD 2.62 million Calculation and evidence 2744000 − 128000 USD Exact free cash flow: 2616000 USD 2019-01-01 – 2019-12-31: 2744000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 128000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2019-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: 2616000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 2744000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315221005827/ntn-20201231.xml#121399 Filing: 000149315221005827 Input fundies:CapitalExpenditure: 128000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315220018754/ntn-20200630.xml#414700 Filing: 000149315220018754 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 4.42 million Exact value Exact value: -4415000 USD 2020-01-01 – 2020-12-31: -4415000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2020-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -4415000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4415000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315221005827/ntn-20201231.xml#110750 Filing: 000149315221005827 The citation records this snapshot. The page link may show a newer release later.	−USD 3.89 million Exact value Exact value: -3894000 USD 2020-01-01 – 2020-12-31: -3894000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2020-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: -3894000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3894000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315221005827/ntn-20201231.xml#121213 Filing: 000149315221005827 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 21.67 million Exact value Exact value: -21668000 USD 2023-01-01 – 2023-12-31: -21668000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2023-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -21668000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21668000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#2497252 Filing: 000149315225010051 The citation records this snapshot. The page link may show a newer release later.	−USD 20.41 million Exact value Exact value: -20408000 USD 2023-01-01 – 2023-12-31: -20408000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2023-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: -20408000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20408000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#1508058 Filing: 000149315225010051 The citation records this snapshot. The page link may show a newer release later.	USD 19,000 Exact value Exact value: 19000 USD 2023-01-01 – 2023-12-31: 19000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2023-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 19000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#1510703 Filing: 000149315225010051 The citation records this snapshot. The page link may show a newer release later.	−USD 20.43 million Calculation and evidence -20408000 − 19000 USD Exact free cash flow: -20427000 USD 2023-01-01 – 2023-12-31: -20408000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 19000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2023-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: -20427000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20408000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#1508058 Filing: 000149315225010051 Input fundies:CapitalExpenditure: 19000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315225010051/form10-k.htm#1510703 Filing: 000149315225010051 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 44.54 million Exact value Exact value: -44539000 USD 2024-01-01 – 2024-12-31: -44539000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Net Income: -44539000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44539000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1814215 Filing: 000149315226010102 The citation records this snapshot. The page link may show a newer release later.	−USD 15.84 million Exact value Exact value: -15836000 USD 2024-01-01 – 2024-12-31: -15836000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Operating Cash Flow: -15836000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15836000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1578404 Filing: 000149315226010102 The citation records this snapshot. The page link may show a newer release later.	USD 369,000 Exact value Exact value: 369000 USD 2024-01-01 – 2024-12-31: 369000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Capital Expenditure: 369000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 369000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1581064 Filing: 000149315226010102 The citation records this snapshot. The page link may show a newer release later.	−USD 16.21 million Calculation and evidence -15836000 − 369000 USD Exact free cash flow: -16205000 USD 2024-01-01 – 2024-12-31: -15836000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 369000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ernexa Therapeutics Inc. · 2024-12-31 Ernexa Therapeutics Inc. (edgar:748592) Free cash flow: -16205000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:25:20Z Snapshot: aaaea9c079a73bf8088eabcdb9c68be0b299ab4a1b74a87357b0451461d4b608 Dimensions: Consolidated View: https://fundies.io/companies/edgar/748592?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15836000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1578404 Filing: 000149315226010102 Input fundies:CapitalExpenditure: 369000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/form10-k.htm#1581064 Filing: 000149315226010102 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

213 filings · 4,624 latest values · 4,624 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000748592, 748592, BTX, ERNA, ERNAW, NTN, edgar:748592

Also known as Brooklyn ImmunoTherapeutics, Inc., Ernexa Therapeutics Inc., Eterna Therapeutics Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC

Ernexa Therapeutics Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation